Orchestra Biomed Holdings Inc (OBIO)

$5.61

-0.18

(-3.11%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $5.50
    $5.99
    $5.61
    downward going graph

    1.96%

    Downside

    Day's Volatility :8.18%

    Upside

    6.34%

    downward going graph
  • $4.22
    $11.69
    $5.61
    downward going graph

    24.78%

    Downside

    52 Weeks Volatility :63.9%

    Upside

    52.01%

    downward going graph

Returns

PeriodOrchestra Biomed Holdings IncIndex (Russel 2000)
3 Months
-29.7%
0.0%
6 Months
-13.56%
0.0%
1 Year
-9.52%
0.0%
3 Years
-51.22%
-22.3%

Highlights

Market Capitalization
219.0M
Book Value
$1.23
Earnings Per Share (EPS)
-1.56
Wall Street Target Price
15.6
Profit Margin
0.0%
Operating Margin TTM
-2166.97%
Return On Assets TTM
-36.75%
Return On Equity TTM
-83.22%
Revenue TTM
2.1M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-15.0%
Gross Profit TTM
0.0
EBITDA
-58.0M
Diluted Eps TTM
-1.56
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.68
EPS Estimate Next Year
-1.76
EPS Estimate Current Quarter
-0.39
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Orchestra Biomed Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 178.07%

Current $5.61
Target $15.60

Company Financials

FY20Y/Y Change
Revenue
5.7M
-
Net Income
-21.4M
-
Net Profit Margin
-374.45%
-
FY21Y/Y Change
Revenue
-782.0K
↓ 113.71%
Net Income
-23.0M
↑ 7.77%
Net Profit Margin
2.9K%
↑ 3317.42%
FY22Y/Y Change
Revenue
3.5M
↓ 551.79%
Net Income
-33.6M
↑ 46.03%
Net Profit Margin
-951.26%
↓ 3894.23%
FY23Y/Y Change
Revenue
2.8M
↓ 21.88%
Net Income
-49.1M
↑ 46.16%
Net Profit Margin
-1.8K%
↓ 828.45%
Q1 FY23Q/Q Change
Revenue
1.2M
↑ 5.53%
Net Income
-10.9M
↑ 1147.83%
Net Profit Margin
-939.86%
↓ 860.37%
Q2 FY23Q/Q Change
Revenue
915.0K
↓ 21.39%
Net Income
-12.0M
↑ 10.11%
Net Profit Margin
-1.3K%
↓ 376.64%
Q3 FY23Q/Q Change
Revenue
419.0K
↓ 54.21%
Net Income
-13.3M
↑ 10.54%
Net Profit Margin
-3.2K%
↓ 1861.54%
Q4 FY23Q/Q Change
Revenue
262.0K
↓ 37.47%
Net Income
-12.8M
↓ 3.74%
Net Profit Margin
-4.9K%
↓ 1714.33%
Q1 FY24Q/Q Change
Revenue
620.0K
↑ 136.64%
Net Income
-13.5M
↑ 5.03%
Net Profit Margin
-2.2K%
↑ 2720.92%
Q2 FY24Q/Q Change
Revenue
778.0K
↑ 25.48%
Net Income
-16.0M
↑ 18.7%
Net Profit Margin
-2.1K%
↑ 117.47%
FY20Y/Y Change
Total Assets
38.1M
-
Total Liabilities
86.6M
-
FY21Y/Y Change
Total Assets
13.5M
↓ 64.49%
Total Liabilities
84.8M
↓ 2.16%
FY22Y/Y Change
Total Assets
95.6M
↑ 606.53%
Total Liabilities
43.0M
↓ 49.22%
FY23Y/Y Change
Total Assets
95.2M
↓ 0.38%
Total Liabilities
27.2M
↓ 36.87%
Q1 FY23Q/Q Change
Total Assets
136.3M
↑ 100.19%
Total Liabilities
36.5M
↑ 397.4%
Q2 FY23Q/Q Change
Total Assets
125.9M
↓ 7.63%
Total Liabilities
36.4M
↓ 0.23%
Q3 FY23Q/Q Change
Total Assets
116.4M
↓ 7.57%
Total Liabilities
36.7M
↑ 0.71%
Q4 FY23Q/Q Change
Total Assets
95.2M
↓ 18.17%
Total Liabilities
27.2M
↓ 25.97%
Q1 FY24Q/Q Change
Total Assets
82.6M
↓ 13.22%
Total Liabilities
25.4M
↓ 6.36%
Q2 FY24Q/Q Change
Total Assets
72.4M
↓ 12.4%
Total Liabilities
28.3M
↑ 11.08%
FY20Y/Y Change
Operating Cash Flow
-26.2M
-
Investing Cash Flow
27.0M
-
Financing Cash Flow
10.0M
-
FY21Y/Y Change
Operating Cash Flow
-19.4M
↓ 25.8%
Investing Cash Flow
13.0M
↓ 51.73%
Financing Cash Flow
-4.0M
↓ 139.93%
Q1 FY23Q/Q Change
Operating Cash Flow
-14.4M
↑ 64.47%
Investing Cash Flow
8.1M
↑ 0.0%
Financing Cash Flow
56.8M
↓ 1216.33%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.5M
↓ 27.06%
Investing Cash Flow
8.1M
↑ 0.0%
Financing Cash Flow
86.0K
↓ 99.85%

Technicals Summary

Sell

Neutral

Buy

Orchestra Biomed Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings Inc
-3.77%
-13.56%
-9.52%
-51.22%
-51.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings Inc
NA
NA
NA
-1.68
-0.83
-0.37
NA
1.23
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings Inc
Buy
$219.0M
-51.22%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Orchestra Biomed Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 262.0K → 778.0K (in $), with an average increase of 39.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -12.81M → -15.98M (in $), with an average decrease of 11.9% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 46.6%

Company Information

Organization
Orchestra Biomed Holdings Inc
Employees
56
CEO
Mr. David P. Hochman
Industry
Miscellaneous

Discover More

FAQs